Recombinant Human TIMP2/CSC-21K Protein, His-Tag, 50µg

Background
TIMP metallopeptidase inhibitor 2 also known as TIMP2, which belongs to the protease inhibitor I35 (TIMP) family. This family protein are natural inhibitors of the matrix metalloproteinases, a group of peptidases involved in degradation of the extracellular matrix. The TIMP family encompasses four members (TIMP1, TIMP2, TIMP3, TIMP4), and they inhibit most MMPs by forming non-covalent binary complex. In addition to an inhibitory role against metalloproteinases, TIMP2 has a unique role among TIMP family members in its ability to directly suppress the proliferation of endothelial cells. As a result, TIMP-2 may be critical to the maintenance of tissue homeostasis by suppressing the proliferation of quiescent tissues in response to angiogenic factors, and by inhibiting protease activity in tissues undergoing remodelling of the extracellular matrix.

Source
Recombinant Human CSC-21K /TIMP2 Protein (rhTIMP2), His Tag (TI2-H5223) is expressed from human 293 cells (HEK293). It contains AA Cys 27 - Pro 220 (Accession # NP_003246.1).
Predicted N-terminus: Cys 27

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 22.6 kDa. The protein migrates as 23-26 kDa under reducing (R) condition (SDS-PAGE).

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
n/a

Clinical and Translational Updates

(1) "Exosomal proteomics identifies RAB13 as a potential regulator of metastasis for HCC
Huang, Zhang, Li et al
Hepatol Commun (2023) 7 (1), e0006
(2) "Differential effects of poly(ADP ribose) polymerase inhibitor-based metronomic therapy on programmed death-ligand 1 and matrix-associated factors in human myeloid cells
Ibba, Luu, Boulares
Am J Transl Res (2022) 14 (12), 9025-9030
(3) "The Biology and Function of Tissue Inhibitor of Metalloproteinase 2 in the Lungs
Costanzo, Soto, Meier et al
Pulm Med (2022) 2022, 3632764
Showing 1-3 of 7862 papers.